Mandate

Vinge advises Astrego Diagnostics AB in conjunction with capital procurement

January 29, 2020 M&A

Vinge has advised Astrego Diagnostics AB in connection with the investment in the company by the Japanese company Sysmex Corporation, which has acquired approximately 25% of the shares in the company.

Astrego develops a ground‑breaking technology for characterization of antibiotic‑sensitivity. The first product gives doctors a patient specific diagnostic tool for urinary infections.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg and Viktoria Owetz Leyva.

Related

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025